John Termini

Dr. John Termini

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RTRuijie D. Teo
Ruijie D. Teo
JTJohn Termini
John Termini
HGHarry Gray
Harry Gray

19 October 2016 in Chemical Reviews
Verified
Journal Article
Closed access
RTRuijie D. Teo
Ruijie D. Teo
JHJae Youn Hwang
Jae Youn Hwang
JTJohn Termini
John Termini
ZGZeev Gross
Zeev Gross
HGHarry Gray
Harry Gray

5 September 2014 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
RTRuijie D. Teo
Ruijie D. Teo
HGHarry Gray
Harry Gray
PLPunnajit Lim
Punnajit Lim
JTJohn Termini
John Termini
EDElena Domeshek
Elena Domeshek
ZGZeev Gross
Zeev Gross
We have synthesized and characterized a water-soluble gold(III) corrole (1-Au) that is highly toxic to cisplatin-resistant cancer cells. Relative to its 1-Ga analogue, axial ligands bind only weakly to 1-Au, which likely accounts for its lower affinity for human serum albumin (HSA). We suggest that the cytotoxicity of 1-Au may be related to this lower HSA affinity.

23 September 2008 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
TSTimothy Synold
Timothy Synold
BXBixin Xi
Bixin Xi
GWGerald E. Wuenschell
Gerald E. Wuenschell
DTDaniel Tamae
Daniel Tamae
JFJames L. Figarola
James L. Figarola
JTJohn Termini
John Termini

11 February 2011 in Biochemistry
Verified
Journal Article
Closed access
DTDaniel Tamae
Daniel Tamae
PLPunnajit Lim
Punnajit Lim
GWGerald E. Wuenschell
Gerald E. Wuenschell
JTJohn Termini
John Termini

2 July 2022 in Journal of Neurochemistry
Verified
Journal Article
Open access
MMMelissa Conti Mazza
Melissa Conti Mazza
SSSarah C. Shuck
Sarah C. Shuck
JLJiusheng Lin
Jiusheng Lin
MMMichael A. Moxley
Michael A. Moxley
JTJohn Termini
John Termini
MWMark Wilson
Mark Wilson
Human DJ‐1 is a cytoprotective protein whose absence causes Parkinson's disease and is also associated with other diseases. DJ‐1 has an established role as a redox‐regulated protein that defends against oxidative stress and mitochondrial dysfunction. Multiple studies have suggested that DJ‐1 is also a protein/nucleic acid deglycase that plays a key role in the repair of glycation damage caused by methylglyoxal (MG), a reactive α‐keto aldehyde formed by central metabolism. Contradictory reports suggest that DJ‐1 is a glyoxalase but not a deglycase and does not play a major role in glycation defense. Resolving this issue is important for understanding how DJ‐1 protects cells against insults that can cause disease. We find that DJ‐1 reduces levels of reversible adducts of MG with guanine and cysteine in vitro. The steady‐state kinetics of DJ‐1 acting on reversible hemithioacetal substrates are fitted adequately with a computational kinetic model that requires only a DJ‐1 glyoxalase activity, supporting the conclusion that deglycation is an apparent rather than a true activity of DJ‐1. Sensitive and quantitative isotope‐dilution mass spectrometry shows that DJ‐1 modestly reduces the levels of some irreversible guanine and lysine glycation products in primary and cultured neuronal cell lines and whole mouse brain, consistent with a small but measurable effect on total neuronal glycation burden. However, DJ‐1 does not improve cultured cell viability in exogenous MG. In total, our results suggest that DJ‐1 is not a deglycase and has only a minor role in protecting neurons against methylglyoxal toxicity. image